Your browser is no longer supported. Please, upgrade your browser.
BLPH Bellerophon Therapeutics, Inc. monthly Stock Chart
BLPH [NASD]
Bellerophon Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.31 Insider Own0.70% Shs Outstand9.49M Perf Week9.75%
Market Cap84.29M Forward P/E- EPS next Y-2.33 Insider Trans20.83% Shs Float7.76M Perf Month-3.30%
Income-20.80M PEG- EPS next Q-0.91 Inst Own43.80% Short Float2.10% Perf Quarter-24.83%
Sales- P/S- EPS this Y-554.00% Inst Trans1.25% Short Ratio3.45 Perf Half Y-35.96%
Book/sh4.83 P/B1.82 EPS next Y31.30% ROA-57.60% Target Price- Perf Year60.59%
Cash/sh5.63 P/C1.56 EPS next 5Y- ROE-79.20% 52W Range3.19 - 26.00 Perf YTD67.38%
Dividend- P/FCF- EPS past 5Y47.70% ROI- 52W High-72.15% Beta-0.08
Dividend %- Quick Ratio6.10 Sales past 5Y- Gross Margin- 52W Low127.25% ATR0.58
Employees18 Current Ratio6.10 Sales Q/Q- Oper. Margin- RSI (14)35.40 Volatility6.71% 7.29%
OptionableNo Debt/Eq0.00 EPS Q/Q11.20% Profit Margin- Rel Volume11.62 Prev Close8.78
ShortableYes LT Debt/Eq0.00 EarningsNov 05 BMO Payout- Avg Volume47.17K Price7.24
Recom1.70 SMA20-15.67% SMA50-22.60% SMA200-35.53% Volume401,314 Change-17.54%
Aug-11-20Initiated Jefferies Buy $19
Jan-24-19Initiated Maxim Group Buy $3
Apr-17-17Initiated Ladenburg Thalmann Buy $4.50
Jan-20-17Initiated H.C. Wainwright Buy $5
Mar-22-16Reiterated Leerink Partners Outperform $11 → $9
Jul-27-15Reiterated FBR Capital Outperform $23 → $11
Mar-16-15Initiated FBR Capital Outperform $23
Nov-23-20 08:30AM  
Nov-11-20 08:30AM  
Nov-05-20 10:05AM  
08:30AM  
Oct-29-20 08:30AM  
Sep-14-20 11:49AM  
08:30AM  
Aug-11-20 08:30AM  
Aug-05-20 08:30AM  
Jul-15-20 08:30AM  
Jul-13-20 08:30AM  
Jun-29-20 08:00AM  
Jun-04-20 06:42PM  
May-29-20 03:40PM  
May-22-20 09:47AM  
May-19-20 06:53PM  
07:00AM  
May-18-20 04:03PM  
May-12-20 10:09AM  
May-11-20 04:01PM  
08:30AM  
May-04-20 08:30AM  
Apr-17-20 12:19PM  
Apr-08-20 08:23PM  
08:30AM  
Apr-06-20 10:23AM  
Apr-01-20 01:06PM  
Mar-31-20 08:30AM  
Mar-30-20 09:57AM  
08:00AM  
Mar-29-20 03:44PM  
Mar-23-20 09:30AM  
Mar-22-20 08:19AM  
Mar-20-20 08:30AM  
Mar-10-20 08:30AM  
Feb-21-20 12:11PM  
Feb-19-20 10:32AM  
09:21AM  
07:21AM  
Feb-18-20 08:30AM  
Feb-07-20 12:00PM  
Dec-20-19 04:18PM  
Dec-17-19 08:44AM  
07:00AM  
Nov-12-19 08:30AM  
Nov-07-19 08:30AM  
Nov-06-19 08:30AM  
Nov-01-19 11:51AM  
Oct-28-19 07:15AM  
Oct-23-19 08:30AM  
07:54AM  
Oct-20-19 08:08AM  
Oct-14-19 08:30AM  
Sep-16-19 08:30AM  
Sep-04-19 08:30AM  
Aug-08-19 12:57PM  
08:30AM  
Aug-06-19 08:15PM  
Aug-01-19 08:30AM  
Jun-13-19 08:00AM  
May-22-19 08:30AM  
May-21-19 08:30AM  
May-18-19 09:50AM  
May-13-19 08:30AM  
May-09-19 08:45AM  
08:30AM  
May-03-19 12:10PM  
Apr-08-19 08:30AM  
Mar-18-19 02:08PM  
Mar-14-19 09:09AM  
08:30AM  
Jan-28-19 08:30AM  
Jan-25-19 04:05PM  
Jan-23-19 06:00AM  
Jan-22-19 04:44PM  
Jan-07-19 08:30AM  
Nov-21-18 08:55AM  
Nov-16-18 01:32AM  
Nov-07-18 09:36AM  
08:30AM  
Oct-09-18 08:30AM  
Sep-10-18 11:40AM  
Aug-29-18 08:00AM  
Aug-20-18 08:00AM  
Aug-08-18 08:15AM  
Aug-07-18 08:30AM  
Aug-01-18 09:16AM  
08:40AM  
Jun-15-18 09:13AM  
Jun-12-18 08:39AM  
08:00AM  
Jun-11-18 12:45PM  
09:08AM  
May-16-18 08:30AM  
May-10-18 08:45AM  
May-08-18 08:30AM  
Apr-30-18 08:43AM  
Apr-19-18 09:35AM  
Apr-03-18 08:30AM  
Mar-27-18 07:00AM  
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase II dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FARES WassimChief Medical OfficerSep 10Buy10.184,00040,7084,000Sep 14 08:31 AM
Wang Theodore TDirectorJun 08Buy12.872,60033,45460,913Jun 09 04:01 PM
Wang Theodore TDirectorJun 05Buy12.724,98663,44258,313Jun 09 04:01 PM
Wang Theodore TDirectorNov 25Buy0.397,1932,774592,922Nov 25 04:52 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.